Drugs and Devices

FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome

On Feb. 17, the U.S. Food and Drug Administration (FDA) announced the approval of Korlym (mifepristone) to control hyperglycemia in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares